Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signaling axis plays an important role in normal organ, vascular, and skeletal development. Deregulation of FGFR signaling through genetic modification or overexpression of the receptors (or their ligands) has been observed in numerous tumor settings, whereas the FGF/FGFR axis also plays a key role in driving tumor angiogenesis. A growing body of preclinical data shows that inhibition of FGFR signaling can result in antiproliferative and/or proapoptotic effects, both in vitro and in vivo, thus confirming the validity of the FGF/FGFR axis as a potential therapeutic target. In the past, development of therapeutic approaches to target this axis has been hampered by our inability to develop FGFR-selective agents.With the advent of a number of newmodalities for selectively inhibiting FGF/FGFR signaling, we are now in a unique position to test and validate clinically the many hypotheses that have been generated preclinically. Clin Cancer Res; 18(7); 1–8. 2012 AACR.

[1]  W. Sellers,et al.  FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[3]  Daohong Chen,et al.  A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models , 2011, Molecular Cancer Therapeutics.

[4]  M. Mohammadi,et al.  Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. , 2011, American journal of physiology. Renal physiology.

[5]  J. Wesche,et al.  Fibroblast growth factors and their receptors in cancer. , 2011, The Biochemical journal.

[6]  M. Dennis,et al.  Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 , 2011, mAbs.

[7]  J. Baselga,et al.  A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Lincoln D. Stein,et al.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. , 2011, Cancer cell.

[9]  L. Quarles,et al.  Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. , 2011, American journal of physiology. Endocrinology and metabolism.

[10]  T. Mohr,et al.  Up‐regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis , 2011, Hepatology.

[11]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[12]  Nhi N. Y. Vo,et al.  GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. , 2010, Cancer research.

[13]  Lihong V Wang,et al.  Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts , 2010, Clinical Cancer Research.

[14]  L. Medeiros,et al.  8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.

[15]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[16]  L. Staudt,et al.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.

[17]  M. Mohammadi,et al.  FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. , 2009, American journal of physiology. Renal physiology.

[18]  D. Dornan,et al.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.

[19]  C. Der,et al.  Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform* , 2009, Journal of Biological Chemistry.

[20]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[21]  P. Bunn,et al.  Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.

[22]  L. Quarles,et al.  FGFR3 and FGFR4 do not mediate renal effects of FGF23. , 2008, Journal of the American Society of Nephrology : JASN.

[23]  Gordon B. Mills,et al.  Derailed endocytosis: an emerging feature of cancer , 2008, Nature Reviews Cancer.

[24]  Kristian Cibulskis,et al.  Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.

[25]  Cem Elbi,et al.  FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. , 2008, Cancer research.

[26]  R. Carano,et al.  Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models , 2008, Oncogene.

[27]  Ross S Berkowitz,et al.  Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Peter Bohlen,et al.  Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. , 2007, American journal of physiology. Endocrinology and metabolism.

[29]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[30]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[31]  N. Sebire,et al.  FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. , 2006, The EMBO journal.

[32]  K. Rosenblatt,et al.  Regulation of Fibroblast Growth Factor-23 Signaling by Klotho* , 2006, Journal of Biological Chemistry.

[33]  B. Thisse,et al.  Functions and regulations of fibroblast growth factor signaling during embryonic development. , 2005, Developmental biology.

[34]  T. Dragani,et al.  FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. , 2005, Oncology reports.

[35]  Alan P. Brown,et al.  Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor , 2005, Toxicologic pathology.

[36]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[37]  Shaun K Olsen,et al.  Structural basis for fibroblast growth factor receptor activation. , 2005, Cytokine & growth factor reviews.

[38]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[39]  Y. Shiratori,et al.  Altered expression of vascular endothelial growth factor, fibroblast growth factor‐2 and endostatin in patients with hepatocellular carcinoma , 2005, Journal of gastroenterology and hepatology.

[40]  Tomoko Iwata,et al.  Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Joensuu,et al.  High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  G. Frantz,et al.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. , 2002, The American journal of pathology.

[43]  J. Yang,et al.  Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. , 2001, Cancer research.

[44]  M. Makuuchi,et al.  Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. , 1999, Cancer research.

[45]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[46]  M. C. Hu,et al.  FGF-18, a Novel Member of the Fibroblast Growth Factor Family, Stimulates Hepatic and Intestinal Proliferation , 1998, Molecular and Cellular Biology.

[47]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[48]  T. Ueno,et al.  Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. , 1997, Journal of hepatology.

[49]  D. Becker,et al.  Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.

[50]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[51]  C. MacArthur,et al.  Receptor Specificity of the Fibroblast Growth Factor Family* , 1996, The Journal of Biological Chemistry.

[52]  L. Shulman,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2008 .

[53]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.